Ex vivo expanded human circulating Vδ1 γδT cells exhibit favorable therapeutic potential for colon cancer

References

• Chien YH, Meyer C, Bonneville M. gammadelta T cells: first line of defense and beyond. Annu Rev Immunol 2014;32:121-55; PMID:24387714; http://dx.doi.org/10.1146/annurev-immunol-032713-120216
   PubMed Web of Science ®Google Scholar
• Groh V, Porcelli S, Fabbi M, Lanier LL, Picker LJ, Anderson T, Warnke RA, Bhan AK, Strominger JL, Brenner MB. Human lymphocytes bearing T cell receptor gamma/delta are phenotypically diverse and evenly distributed throughout the lymphoid system. J Exp Med 1989;169:1277-94; PMID:2564416; http://dx.doi.org/10.1084/jem.169.4.1277
   PubMed Web of Science ®Google Scholar
• Hayday AC. ; gamma; delta cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000;18:975-1026; PMID:10837080; http://dx.doi.org/10.1146/annurev.immunol.18.1.975
   PubMed Web of Science ®Google Scholar
• Bottino C, Tambussi G, Ferrini S, Ciccone E, Varese P, Mingari MC, Moretta L, Moretta A. Two subsets of human T lymphocytes expressing gamma/delta antigen receptor are identifiable by monoclonal antibodies directed to two distinct molecular forms of the receptor. J Exp Med 1988;168:491-505; PMID:2970517; http://dx.doi.org/10.1084/jem.168.2.491
   PubMed Web of Science ®Google Scholar
• Castella B, Vitale C, Coscia M, Massaia M. Vgamma9Vdelta2 T cell-based immunotherapy in hematological malignancies: from bench to bedside. Cell Mol Life Sci 2011;68:2419-32; PMID:21584812; http://dx.doi.org/10.1007/s00018-011-0704-8
   PubMed Web of Science ®Google Scholar
• Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003;102:200-6; PMID:12623838; http://dx.doi.org/10.1182/blood-2002-12-3665
   PubMed Web of Science ®Google Scholar
• Gomes AQ, Martins DS, Silva-Santos B. Targeting gammadelta T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application. Cancer Res 2010;70:10024-7; PMID:21159627; http://dx.doi.org/10.1158/0008-5472.CAN-10-3236
   PubMed Web of Science ®Google Scholar
• Braza MS, Klein B. Anti-tumour immunotherapy with Vgamma9Vdelta2 T lymphocytes: from the bench to the bedside. Br J Haematol 2013;160:123-32; PMID:23061882; http://dx.doi.org/10.1111/bjh.12090
   PubMed Web of Science ®Google Scholar
• Nicol AJ, Tokuyama H, Mattarollo SR, Hagi T, Suzuki K, Yokokawa K, Nieda M. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer 2011;105:778-86; PMID:21847128; http://dx.doi.org/10.1038/bjc.2011.293
   PubMed Web of Science ®Google Scholar
• Kunzmann V, Smetak M, Kimmel B, Weigang-Koehler K, Goebeler M, Birkmann J, Becker J, Schmidt-Wolf IG, Einsele H, Wilhelm M. Tumor-promoting versus tumor-antagonizing roles of gammadelta T cells in cancer immunotherapy: results from a prospective phase I/II trial. J Immunother 2012;35:205-13; PMID:22306909; http://dx.doi.org/10.1097/CJI.0b013e318245bb1e
   PubMed Web of Science ®Google Scholar
• Noguchi A, Kaneko T, Kamigaki T, Fujimoto K, Ozawa M, Saito M, Ariyoshi N, Goto S. Zoledronate-activated Vgamma9gammadelta T cell-based immunotherapy is feasible and restores the impairment of gammadelta T cells in patients with solid tumors. Cytotherapy 2011;13:92-7; PMID:20831354; http://dx.doi.org/10.3109/14653249.2010.515581
   PubMed Web of Science ®Google Scholar
• Bonneville M, O'Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 2010;10:467-78; PMID:20539306; http://dx.doi.org/10.1038/nri2781
   PubMed Web of Science ®Google Scholar
• Maeurer MJ, Martin D, Walter W, Liu K, Zitvogel L, Halusczcak K, Rabinowich H, Duquesnoy R, Storkus W, Lotze MT. Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin. J Exp Med 1996;183:1681-96; PMID:8666926; http://dx.doi.org/10.1084/jem.183.4.1681
   PubMed Web of Science ®Google Scholar
• Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A 1999;96:6879-84; PMID:10359807; http://dx.doi.org/10.1073/pnas.96.12.6879
   PubMed Web of Science ®Google Scholar
• Knight A, Mackinnon S, Lowdell MW. Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells. Cytotherapy 2012;14:1110-8; PMID:22800570; http://dx.doi.org/10.3109/14653249.2012.700766
   PubMed Web of Science ®Google Scholar
• Siegers GM, Dhamko H, Wang XH, Mathieson AM, Kosaka Y, Felizardo TC, Medin JA, Tohda S, Schueler J, Fisch P et al. Human Vdelta1 gammadelta T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells. Cytotherapy 2011;13:753-64; PMID:21314241; http://dx.doi.org/10.3109/14653249.2011.553595
   PubMed Web of Science ®Google Scholar
• Knight A, Arnouk H, Britt W, Gillespie GY, Cloud GA, Harkins L, Su Y, Lowdell MW, Lamb LS. CMV-independent lysis of glioblastoma by ex vivo expanded/activated Vdelta1+ gammadelta T cells. PLoS One 2013;8:e68729; PMID:23950874; http://dx.doi.org/10.1371/journal.pone.0068729
   PubMed Web of Science ®Google Scholar
• Halary F, Pitard V, Dlubek D, Krzysiek R, de la Salle H, Merville P, Dromer C, Emilie D, Moreau JF, Dechanet-Merville J. Shared reactivity of V{delta}2(neg) {gamma}{delta} T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells. J Exp Med 2005;201:1567-78; PMID:15897274; http://dx.doi.org/10.1084/jem.20041851
   PubMed Web of Science ®Google Scholar
• Benzaid I, Monkkonen H, Bonnelye E, Monkkonen J, Clezardin P. In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vgamma9Vdelta2 T-cell antitumor cytotoxicity through ICAM-1 engagement. Clin Cancer Res 2012;18:6249-59; PMID:23032740; http://dx.doi.org/10.1158/1078-0432.CCR-12-0918
   PubMed Web of Science ®Google Scholar
• Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, Wang Z, Wang C, Zhang Z, Xia W et al. gammadeltaT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 2014;40:785-800; PMID:24816404; http://dx.doi.org/10.1016/j.immuni.2014.03.013
   PubMed Web of Science ®Google Scholar
• Delmas D, Rebe C, Micheau O, Athias A, Gambert P, Grazide S, Laurent G, Latruffe N, Solary E. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene 2004;23:8979-86; PMID:15480430; http://dx.doi.org/10.1038/sj.onc.1208086
   PubMed Web of Science ®Google Scholar
• Todaro M, D'Asaro M, Caccamo N, Iovino F, Francipane MG, Meraviglia S, Orlando V, La Mendola C, Gulotta G, Salerno A et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 2009;182:7287-96; PMID:19454726; http://dx.doi.org/10.4049/jimmunol.0804288
   PubMed Web of Science ®Google Scholar
• Dippold W, Wittig B, Schwaeble W, Mayet W, Meyer zum Buschenfelde KH. Expression of intercellular adhesion molecule 1 (ICAM-1, CD54) in colonic epithelial cells. Gut 1993;34:1593-7; PMID:7902311; http://dx.doi.org/10.1136/gut.34.11.1593
   PubMed Web of Science ®Google Scholar
• Kondo M, Izumi T, Fujieda N, Kondo A, Morishita T, Matsushita H, Kakimi K. Expansion of human peripheral blood gammadelta T cells using zoledronate. J Vis Exp 2011; 55:3182; PMID:21931292; http://dx.doi.org/10.3791/3182
   PubMedGoogle Scholar
• Correia DV, Fogli M, Hudspeth K, da Silva MG, Mavilio D, Silva-Santos B. Differentiation of human peripheral blood Vdelta1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 2011;118:992-1001; PMID:21633088; http://dx.doi.org/10.1182/blood-2011-02-339135
   PubMed Web of Science ®Google Scholar
• Donia M, Ellebaek E, Andersen MH, Straten PT, Svane IM. Analysis of Vdelta1 T cells in clinical grade melanoma-infiltrating lymphocytes. Oncoimmunology 2012;1:1297-304; PMID:23243593; http://dx.doi.org/10.4161/onci.21659
   PubMed Web of Science ®Google Scholar
• Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 2007;27:334-48; PMID:17656116; http://dx.doi.org/10.1016/j.immuni.2007.05.020
   PubMed Web of Science ®Google Scholar
• Schilbach K, Frommer K, Meier S, Handgretinger R, Eyrich M. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy. J Immunother 2008;31:896-905; PMID:18832998; http://dx.doi.org/10.1097/CJI.0b013e31818955ad
   PubMed Web of Science ®Google Scholar
• Maeurer M, Zitvogel L, Elder E, Storkus WJ, Lotze MT. Human intestinal V delta 1+ T cells obtained from patients with colon cancer respond exclusively to SEB but not to SEA. Nat Immun 1995;14:188-97; PMID:8696008
   PubMedGoogle Scholar
• Deniger DC, Maiti S, Mi T, Switzer K, Ramachandran V, Hurton LV, Ang S, Olivares S, Rabinovich BA, Huls H et al. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res 2014; 20(22):5708-19; PMID:24833662; http://dx.doi.org/10.1158/1078-0432
   PubMed Web of Science ®Google Scholar
• Fisher J, Yan M, Heuijerjans J, Carter L, Abolhassani A, Frosch J, Wallace R, Flutter B, Hubank M, Klein N et al. Neuroblastoma killing properties of V-delta 2 and V-delta2 negative gamma delta T cells following expansion by artificial antigen presenting cells. Clin Cancer Res 2014; 20(22):5720-32; http://dx.doi.org/10.1158/1078-0432
   PubMed Web of Science ®Google Scholar
• Siegers GM, Ribot EJ, Keating A, Foster PJ. Extensive expansion of primary human gamma delta T cells generates cytotoxic effector memory cells that can be labeled with Feraheme for cellular MRI. Cancer Immunol Immunother 2013;62:571-83; PMID:23100099; http://dx.doi.org/10.1007/s00262-012-1353-y
   PubMed Web of Science ®Google Scholar
• Dokouhaki P, Han M, Joe B, Li M, Johnston MR, Tsao MS, Zhang L. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach. Cancer Lett 2010;297:126-36; PMID:20537791; http://dx.doi.org/10.1016/j.canlet.2010.05.005
   PubMed Web of Science ®Google Scholar
• Peters C, Oberg HH, Kabelitz D, Wesch D. Phenotype and regulation of immunosuppressive Vdelta2-expressing gammadelta T cells. Cell Mol Life Sci 2014;71:1943-60; PMID:24091816; http://dx.doi.org/10.1007/s00018-013-1467-1
   PubMed Web of Science ®Google Scholar
• Hua F, Kang N, Gao YA, Cui LX, Ba DN, He W. Potential regulatory role of in vitro-expanded Vdelta1 T cells from human peripheral blood. Immunol Res 2013;56:172-80; PMID:23532670; http://dx.doi.org/10.1007/s12026-013-8390-2
   PubMed Web of Science ®Google Scholar
• Iwasaki M, Tanaka Y, Kobayashi H, Murata-Hirai K, Miyabe H, Sugie T, Toi M, Minato N. Expression and function of PD-1 in human gammadelta T cells that recognize phosphoantigens. Eur J Immunol 2011;41:345-55; PMID:21268005; http://dx.doi.org/10.1002/eji.201040959
   PubMed Web of Science ®Google Scholar
• Utzschneider DT, Legat A, Fuertes Marraco SA, Carrie L, Luescher I, Speiser DE, Zehn D. T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol 2013;14:603-10; PMID:23644506; http://dx.doi.org/10.1038/ni.2606
   PubMed Web of Science ®Google Scholar
• Ye J, Ma C, Hsueh EC, Eickhoff CS, Zhang Y, Varvares MA, Hoft DF, Peng G. Tumor-derived gammadelta regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence. J Immunol 2013;190:2403-14; PMID:23355732; http://dx.doi.org/10.4049/jimmunol.1202369
   PubMed Web of Science ®Google Scholar
• Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Sato S, Sato K, Hosoi A, Nakajima J, Yoshida Y et al. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 2008;10:842-56; PMID:19016372; http://dx.doi.org/10.1080/14653240802419328
   PubMed Web of Science ®Google Scholar
• Nishio N, Fujita M, Tanaka Y, Maki H, Zhang R, Hirosawa T, Demachi-Okamura A, Uemura Y, Taguchi O, Takahashi Y et al. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human gammadelta T cells. J Immunother 2012;35:598-606; PMID:22996365; http://dx.doi.org/10.1097/CJI.0b013e31826a745a
   PubMed Web of Science ®Google Scholar
• Devaud C, Bilhere E, Loizon S, Pitard V, Behr C, Moreau JF, Dechanet-Merville J, Capone M. Antitumor activity of gammadelta T cells reactive against cytomegalovirus-infected cells in a mouse xenograft tumor model. Cancer Res 2009;69:3971-8; PMID:19383918; http://dx.doi.org/10.1158/0008-5472.CAN-08-3037
   PubMed Web of Science ®Google Scholar
• Shitara S, Hara T, Liang B, Wagatsuma K, Zuklys S, Hollander GA, Nakase H, Chiba T, Tani-ichi S, Ikuta K. IL-7 produced by thymic epithelial cells plays a major role in the development of thymocytes and TCRgammadelta+ intraepithelial lymphocytes. J Immunol 2013;190:6173-9; PMID:23686483; http://dx.doi.org/10.4049/jimmunol.1202573
   PubMed Web of Science ®Google Scholar
• Wang YK, Zhu YL, Qiu FM, Zhang T, Chen ZG, Zheng S, Huang J. Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells. Carcinogenesis 2010;31:1376-80; PMID:20530554; http://dx.doi.org/10.1093/carcin/bgq120
   PubMed Web of Science ®Google Scholar